Therapy News and Research

RSS

Metformin more effective than sulfonylurea in controlling type 2 diabetes

A Vanderbilt study examining the impact of the two most commonly prescribed oral diabetes medications on the risk for heart attack, stroke and death has found the drug metformin has benefits over sulfonylurea drugs.

8 Nov 2012

Thyroid journal publishes new ATA guidelines for management of anaplastic thyroid cancer

Anaplastic thyroid cancer is a rare form of thyroid tumor, but it is also the most deadly. Newly developed evidence-based recommendations for the diagnosis, treatment, and long-term monitoring and follow-up care of patients with this extremely aggressive form of thyroid cancer are published in Thyroid, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

8 Nov 2012

Washington University, SRI investigators launch Global Metabolomic Initiative

Investigators at Washington University and The Scripps Research Institute have announced the launch of a "Global Metabolomic Initiative" to facilitate meta-analyses on studies of the metabolism of bacteria, yeast, plants, animals and people.

7 Nov 2012

Teva announces additional data from QNASL Phase III program on seasonal allergic rhinitis

Teva Pharmaceutical Industries Ltd. announced today that additional data from the Phase III clinical program for QNASL- (beclomethasone dipropionate) Nasal Aerosol will be presented at the 2012 Annual Meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Anaheim, CA on November 8-13, 2012.

7 Nov 2012

WU researchers to study blood-clotting disorders

Researchers at Washington University School of Medicine in St. Louis have received a $9 million grant to investigate blood-clotting disorders. From heart attacks and strokes to uncontrolled bleeding, clotting disorders cause more deaths each year in the United States than all types of cancer combined.

7 Nov 2012

FDA EMDAC votes unanimously in support of Signifor use for treatment of Cushing's disease

The US Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) has voted unanimously in support of the use of Signifor (pasireotide) for the treatment of patients with Cushing's disease who require medical therapeutic intervention.

7 Nov 2012

Cloud technology helps researchers collect detailed information from cancer cell samples

Storing music and photos on distant computers via "cloud" technology is nothing new. But Johns Hopkins researchers are now using this tactic to collect detailed information from thousands of cancer cell samples. The goal is to help doctors make better predictions about how a patient's illness will progress and what type of treatment will be most effective.

7 Nov 2012

Treatment with AMG 145 reduces LDL cholesterol

Amgen today announced that results from the LAPLACE-TIMI 57 and MENDEL Phase 2 studies evaluating AMG 145 in hypercholesterolemic patients with or without statins, respectively, showed that treatment with AMG 145 resulted in a statistically significant reduction in low-density lipoprotein (LDL) cholesterol.

7 Nov 2012

Drug trio may reduce eliminate cardiac side effects of doxorubicin

Combining cancer medication with a drug for erectile dysfunction and one for heart transplants helped kill cancer cells and protected the heart from damage, in a study presented at the American Heart Association's Scientific Sessions 2012.

7 Nov 2012

Lexicon announces data from LX4211 Phase 2b trial on type 2 diabetes

Lexicon Pharmaceuticals, Inc. announced that data from the Phase 2b clinical trial of LX4211 are being presented today as a Clinical Sciences Special Report in the Emerging Therapeutics for Diabetes and Dyslipidemia section of the American Heart Association (AHA) Scientific Sessions Conference held in Los Angeles, California.

7 Nov 2012

Cause of heart attacks or strokes may be different in some patients treated with anti-platelet drugs

The cause of heart attacks or strokes among some patients treated with anti-platelet drugs may be different than for patients who have undergone surgical procedures to restore blood flow, according to researchers at Duke Medicine.

7 Nov 2012

Positive results from BioCardia's Helical Infusion System Phase 1/2 trial on ischemic cardiomyopathy

BioCardia, Inc., focused on regenerative biologic therapies for cardiovascular disease, today announced positive results from a Phase 1/2 heart failure trial using the Company's Helical Infusion System, comprising the Helical Infusion System Catheter and Morph Vascular Access Catheter, to deliver allogeneic, or "off-the-shelf," and autologous, or from the treated patient, mesenchymal (adult) stem cells (MSCs) via transendocardial injection.

7 Nov 2012

AMG 145 can reduce LDL cholesterol levels by up to 66% after 12 weeks

For many people with high cholesterol, statins serve as the first line of treatment. However, some patients are unable to effectively reduce their low-density lipoprotein cholesterol (LDL cholesterol) or "bad cholesterol" levels with statins, the most commonly used medication to treat high cholesterol, due to their bodies' inability to tolerate or sufficiently respond to the medicine.

7 Nov 2012

Positive results from POZEN's PA32540 Phase 3 trials presented at AHA Scientific Sessions 2012

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, presented positive results from two pivotal Phase 3 clinical trials of the investigational product, PA32540, at The American Heart Association (AHA) Scientific Sessions 2012, as Poster #12057: Treatment Continuation and Cardiovascular Safety of Antiplatelet Therapy with PA32540, A Tablet with Enteric-Coated Aspirin and Immediate-Release Omeprazole: Results of Two 6-Month, Phase 3 Studies.

6 Nov 2012

$Cryopraxis/CellPraxis initiates recruitment in ReACT Phase III trial for refractory angina$

Therapy News and Research

Metformin more effective than sulfonylurea in controlling type 2 diabetes

Thyroid journal publishes new ATA guidelines for management of anaplastic thyroid cancer

Washington University, SRI investigators launch Global Metabolomic Initiative

Teva announces additional data from QNASL Phase III program on seasonal allergic rhinitis

WU researchers to study blood-clotting disorders

FDA EMDAC votes unanimously in support of Signifor use for treatment of Cushing's disease

Cloud technology helps researchers collect detailed information from cancer cell samples

Treatment with AMG 145 reduces LDL cholesterol

Drug trio may reduce eliminate cardiac side effects of doxorubicin

Lexicon announces data from LX4211 Phase 2b trial on type 2 diabetes

Cause of heart attacks or strokes may be different in some patients treated with anti-platelet drugs

Positive results from BioCardia's Helical Infusion System Phase 1/2 trial on ischemic cardiomyopathy

AMG 145 can reduce LDL cholesterol levels by up to 66% after 12 weeks

Positive results from POZEN's PA32540 Phase 3 trials presented at AHA Scientific Sessions 2012

Cryopraxis/CellPraxis initiates recruitment in ReACT Phase III trial for refractory angina

Monoclonal antibody boosts cholesterol reduction

Stressful life events linked to bipolar depression

Exercise not superior to physiotherapy for neck pain

Receptor expression sheds light on nasal polyposis

Physical exercise may help preserve mobility in Parkinson’s patients

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News